Sandbox g19
Brain abscess
- Empiric antimicrobial therapy[1]
- Brain abscess in otherwise healthy patients
- Preferred regimen
- (Cefotaxime 8–12 g/day IV q4–6h OR Ceftriaxone 4 g/day IV q12h) AND Metronidazole 30 mg/kg/day IV q6h
- Alternative regimen
- Meropenem 6 g/day IV q8h
- Brain abscess with comorbidities
- Otitis media, mastoiditis, or sinusitis
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Metronidazole 30 mg/kg/day q6h
- Dental infection
- Preferred regimen
- Penicillin G 4 MU IV q4h AND Metronidazole 30 mg/kg/day q6h
- Penetrating trauma or post-neurosurgy
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Vancomycin 30–45 mg/kg/day q8–12h
- Lung abscess, empyema, or bronchiectasis
- Preferred regimen
- Penicillin G 4 MU IV q4h AND Metronidazole 30 mg/kg/day q6h AND TMP-SMZ 10–20 mg/kg/day q6–12h
- Bacterial endocarditis
- Preferred regimen
- Vancomycin 30–45 mg/kg/day q8–12h AND Gentamicin 5 mg/kg/day IV q8h
- Congenital heart disease
- Preferred regimen
- Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h
- Transplant recipients
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Metronidazole 30 mg/kg/day q6h AND Voriconazole 8 mg/kg/day q12h AND (TMP-SMZ 10–20 mg/kg/day q6–12h OR Sulfadiazine 4–6 g/day q6h)
- Patients with HIV/AIDS
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Sulfadiazine 4–6 g/day q6h AND Pyrimethamine 25–100 mg/day qd
- Staphylococcus aureus coverage
- Preferred regimen
- Vancomycin 30–45 mg/kg/day q8–12h
- Mycobacterium tuberculosis coverage
- Preferred regimen
- Isoniazid 300 mg qd AND Rifampin 600 mg qd AND Pyrazinamide 15–30 mg qd AND Ethambutol 15 mg/kg/day qd
- Pathogen-directed antimicrobial therapy[2]
- Bacteria
- Actinomyces
- Preferred regimen
- Penicillin G 4 MU IV q4h
- Alternative regimen
- Clindamycin 2400–4800 mg/day IV q6h
- Bacteroides fragilis
- Preferred regimen
- Metronidazole 30 mg/kg/day IV q6h
- Alternative regimen
- Clindamycin 2400–4800 mg/day IV q6h
- Bacteroides fragilis
- Preferred regimen
- Metronidazole 30 mg/kg/day q6h
- Enterobacteriaceae
- Preferred regimen
- Cefotaxime 2 g IV q4-6h OR Ceftriaxone 2 g IV q12h OR Cefepime 2 g IV q12h
- Fusobacterium
- Preferred regimen
- Metronidazole 30 mg/kg/day q6h
- Haemophilus
- Preferred regimen
- Cefotaxime 2 g IV q4-6h OR Ceftriaxone 2 g IV q12h OR Cefepime 2 g IV q12h
- Listeria monocytogenes
- Preferred regimen
- Ampicillin 12 g/day q4h OR Penicillin G 4 MU IV q4h
- Nocardia
- Preferred regimen
- TMP-SMZ 10–20 mg/kg/day q6–12h OR Sulfadiazine 4–6 g/day q6h
- Prevotella melaninogenica
- Preferred regimen
- Metronidazole 30 mg/kg/day q6h
- Pseudomonas aeruginosa
- Preferred regimen
- Ceftazidime 6 g/day q8h OR Cefepime 6 g/day q8h
- Staphylococcus aureus, methicillin-resistant
- Preferred regimen
- Vancomycin 30–45 mg/kg/day IV q8–12h
- Streptococcus, penicillin-susceptible
- Preferred regimen
- Penicillin G 4 MU IV q4h OR Ampicillin 2 g IV q4h
- Streptococcus, penicillin-resistant
- Preferred regimen
- Cefotaxime 2 g IV q4-6h OR Ceftriaxone 2 g IV q12h OR Cefepime 2 g IV q12h
- Fungi
- Aspergillus
- Preferred regimen
- Voriconazole 8 mg/kg/day q12h
- Candida
- Preferred regimen
- Amphotericin B lipid complex 5 mg/kd/day q24h OR Amphotericin B deoxycholate 15 mg/kg/day q8h
- Cryptococcus neoformans
- Preferred regimen
- Amphotericin B lipid complex 5 mg/kd/day q24h OR Amphotericin B deoxycholate 15 mg/kg/day q8h
- Mucorales
- Preferred regimen
- Amphotericin B lipid complex 5 mg/kd/day q24h OR Amphotericin B deoxycholate 15 mg/kg/day q8h
- Pseudallescheria boydii (Scedosporium apiospermum)
- Preferred regimen
- Voriconazole 8 mg/kg/day q12h
- Protozoa
- Toxoplasma gondii
- Preferred regimen
- Sulfadiazine 4–6 g/day q6h AND Pyrimethamine 25–100 mg/day qd
References
- ↑ Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.
- ↑ Bennett, John (2015). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Elsevier/Saunders. ISBN 978-1455748013.